Sarabia, Naomi A.

HRN: 26-09-08  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/25/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
10/25/2024
11/01/2024
IV
1.5gm
Q6h
Infected Wound
Waiting Final Action 
10/25/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
10/25/2024
11/01/2024
IV
600mg
Q 6 HRS
Infected Wound
Waiting Final Action 
10/27/2024
CEFTAZIDIME 1GM (VIAL)
10/27/2024
11/03/2024
IVTT
1G
Q8
DM Foot
Waiting Final Action 
10/28/2024
CEFTAZIDIME 1GM (VIAL)
10/28/2024
11/04/2024
IV
2g
Q8
Dm Foot
Waiting Final Action 
10/31/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/31/2024
11/07/2024
IV
4.5g
Q8
DM Foot
Waiting Final Action 
11/02/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
11/02/2024
11/30/2024
IVTT
4.5g
Q6
DM FOOT
Waiting Final Action 
11/05/2024
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
11/05/2024
11/12/2024
TOPICAL
25g
BID
Infected Wound
Waiting Final Action 
11/06/2024
LEVOFLOXACIN 500MG (TAB)
11/06/2024
11/12/2024
PO
750mg
OD X7days
HAP
Waiting Final Action 
11/07/2024
FLUCONAZOLE 150MG (CAP)
11/07/2024
11/14/2024
PO
150mg
OD
CAP MR
Waiting Final Action 
11/21/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/21/2024
11/23/2024
IV
600mg
Every 6hours For 6doses Only
S/P Debridement, Left Foot
Waiting Final Action 
11/24/2024
CLINDAMYCIN 300MG (CAP)
11/24/2024
12/01/2024
ORAL
300mg
Tid
Infected Wound
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: